Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN.
Active surveillance
HRQoL
Japanese cohort
Low-risk prostate cancer
Patient‐reported outcome measurement
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
08
09
2020
accepted:
10
10
2020
pubmed:
21
10
2020
medline:
12
1
2022
entrez:
20
10
2020
Statut:
ppublish
Résumé
To evaluate the health-related quality of life (HRQoL) of Japanese men on active surveillance (AS) in the Prostate cancer Research International Active Surveillance study in Japan (PRIAS-JAPAN). Participants were included in the PRIAS-JAPAN HRQoL study between January 2010 and March 2016. Their general HRQoL was assessed using a validated Japanese version of the Short-Form 8 Health Survey (SF-8) at enrolment and annually thereafter until discontinuation of AS. The SF-8 mental component summary (MCS) and physical component summary (PCS) of men on AS were compared with scores of the general population (norm-based score [NBS]: 50) and MCS and PCS scores for men following AS were analysed over time. We tested whether MCS and PCS scores over time explained discontinuation of AS. Five hundred and twenty-five patients enrolled, and the median age at baseline was 68 years. At enrolment and after 1-, 2-, and 3-year follow-ups, the PCS and MCS scores were significantly higher than the NBS of the general Japanese population except for the median PCS at 3 years. We found that age at diagnosis and time on AS negatively affected the PCS score of men on AS, while every additional year on AS led to a 0.27 point increase in MCS scores. Neither PCS nor MCS were predictors for discontinuation of AS. Japanese men following an AS strategy for 3 years reported better HRQoL compared with the general population, indicating that monitoring Japanese low-risk prostate cancer patients can be an effective treatment strategy. Clinical trial registry-UMIN (University Hospital Medical Information Network); UMIN000002874 (2009/12/11).
Identifiants
pubmed: 33079252
doi: 10.1007/s00345-020-03494-4
pii: 10.1007/s00345-020-03494-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2491-2497Informations de copyright
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Mitsuzuka K, Koga H, Sugimoto M et al (2015) Current use of active surveillance for localized prostate cancer: a nationwide survey in Japan. Int J Urol 22:754
doi: 10.1111/iju.12813
Klotz L, Vesprini D, Sethukavalan P et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33:272
doi: 10.1200/JCO.2014.55.1192
Tosoian JJ, Mamawala M, Epstein JI et al (2015) Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 33:3379
doi: 10.1200/JCO.2015.62.5764
Bokhorst LP, Valdagni R, Rannikko A et al (2016) A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol 70:954
doi: 10.1016/j.eururo.2016.06.007
Hamdy FC, Donovan JL, Lane JA et al (2016) 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415
doi: 10.1056/NEJMoa1606220
Clinical Practice Guideline for Prostate Cancer 2016. [Internet]. 2016. Available from: https://www.urol.or.jp/lib/files/other/guideline/23_prostatic_cancer_2016.pdf . Cited 20 Feb 2016
Pearce SM, Wang CHE, Victorson DE et al (2015) A longitudinal study of predictors of sexual dysfunction in men on active surveillance for prostate cancer. Sex Med 3:156
doi: 10.1002/sm2.78
Parker PA, Davis JW, Latini DM et al (2016) Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int 117:469
doi: 10.1111/bju.13099
Venderbos LDF, Van Den Bergh RCN, Roobol MJ et al (2015) A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. Psychooncology 24:348
doi: 10.1002/pon.3657
van den Bergh RCN, Essink-Bot ML, Roobol MJ, Schröder FH, Bangma CH, Steyerberg EW (2010) Do anxiety and distress increase during active surveillance for low risk prostate cancer? J Urol 183:1786
doi: 10.1016/j.juro.2009.12.099
Bokhorst LP, Alberts AR, Rannikko A et al (2015) Compliance rates with the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers. Eur Urol 68:814
doi: 10.1016/j.eururo.2015.06.012
Fukuhara S, Suzukamo Y (2004) Manual of the SF-8 Japanese version: Institute for Health Outcomes & Process Evaluation Research, Kyoto
Kakehi Y, Kamoto T, Shiraishi T et al (2008) Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol 38:122
doi: 10.1093/jjco/hym161
Vasarainen H, Lokman U, Ruutu M, Taari K, Rannikko A (2012) Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial. BJU Int 109:1614
doi: 10.1111/j.1464-410X.2011.10677.x
Kim C, Wright FC, Look Hong NJ et al (2018) Patient and provider experiences with active surveillance: a scoping review. PLoS ONE 13:1
Ruane-McAteer E, Porter S, O’Sullivan J, Dempster M, Prue G (2019) Investigating the psychological impact of active surveillance or active treatment in newly diagnosed favorable-risk prostate cancer patients: a 9-month longitudinal study. Psychooncology 28:1743
doi: 10.1002/pon.5161
Van Hemelrijck M, Ji X, Kattan MW et al (2019) Reasons for discontinuing active surveillance: assessment of 21 centres in 12 countries in the Movember GAP3 Consortium. Eur Urol 75:523
doi: 10.1016/j.eururo.2018.10.025